In models of GVHD, blockade of IL-6 signaling—for instance, through anti-IL-6R antibodies—has been shown to mitigate GVHD severity, accompanied by an expansion of Tregs and a reduction in both Th1 and Th17 populations [11]. The gene discussed is IL6; the disease is graft versus host disease.